20-370 - Study Exploring the Effect of Crizanlizumab on Kidney Function in Patients With Chronic Kidney Disease Caused by Sickle Cell Disease
Status: openA Phase II, multicenter, randomized, open label two arm study comparing the effect of crizanlizumab + standard of care to standard of care alone on renal function in sickle cell disease patients ¡ý 16 years with chronic kidney disease due to sickle cell nephropathy (STEADFAST)
Sickle Cell Disease
Description
This clinical trial will explore the effects of the drug called crizanlizumab has on kidney function in people with long term kidney disease caused by sickle cell disease (SCD).
Interested in Clinical Trial?
Contact the Clinical Trial Coordinator
If you have questions get in touch with this Clinical Trial’s Coordinator by phone at 251-470-5889 or by email at amabien@health.southalabama.edu.
![Johnson Haynes]()
View ProfileJohnson Haynes, Jr., M.D.PulmonologistAssistant Dean of the Office of Diversity and Inclusion; Director of Comprehensive Sickle Cell Center; Professor of Internal Medicine
